Response to February 28, 2009 Office Action

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula (IE) or a salt, or N-oxide, hydrate or solvate thereof, for use in human or veterinary medicine:

$$R_1$$
 R_2
 R_3
(IE)

wherein R_1 has the formula (IIA):

wherein R represents bromo, chloro, phenyl, C₁-C₆ alkyl or phenyl(C₁-C₆ alkyl)

R₂ is hydrogen or

a carboxamide radical; or

a non aromatic carbocyclic or <u>non aromatic</u> heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula $-(Alk^1)_p-(Z)_r(Alk^2)_s-Q$ wherein in any compatible combination Alk^1 and Alk^2 are divalent C_1-C_6 alkylene or C_2-C_6 alkenylene radicals,

Response to February 28, 2009 Office Action

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO₂-, -C(=O)O-, -C(=O)NR^A-, -C(=S)NR^A-, -SO₂NR^A-, -NR^AC(=O)-, -NR^ASO₂- or -NR^A- wherein R^A is hydrogen or C_1 - C_6 alkyl, and

. Q is hydrogen or a carbocyclic or heterocyclic radical;

wherein each of Alk¹, Alk², and Q are optionally substituted with one or more substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, hydroxy(C₁-C₆)alkyl, mercapto, mercapto(C₁-C₆)alkyl, (C₁-C₆)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR^A, -COR^A, -SO₂R^A, -CONH₂, -SO₂NH₂, -CONHR^A, -SO₂NHR^A, -CONR^AR^B, -SO₂NR^AR^B, -NH₂, -NHR^A, -NR^AR^B, -OCONH₂, -OCONHR^A, -OCONR^AR^B, -NHCOR^A, -NHCOOR^A, -NR^BCOOR^A, -NHSO₂OR^A, -NR^BSO₂OR^A, -NHCONH₂, -NR^ACONH₂, -NHCONR^AR^B, or --NR^ACONR^AR^B, wherein R^A and R^B are independently a (C₁-C₆)alkyl group; and

R₃ is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; or a carboxyl, carboxamide or carboxyl ester group,

PROVIDED THAT at least one of R_2 and R_3 is present and is other than hydrogen.

Claims 2-14 (Cancelled)

- 15. (Currently Amended) The compound as claimed in claim 1 wherein R₂ is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.
- 16. (Cancelled)
- 17. (Withdrawn) The compound as claimed in claim 1 wherein R_2 is a carboxamide radical of formula -CONR^B(Alk)_nR^A wherein

Response to February 28, 2009 Office Action

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Withdrawn) The compound as claimed in claim 17 wherein

Alk is an optionally substituted –CH₂-, -CH₂CH₂-, -CH₂CH₂-, CH₂CH=CH-, or –CH₂CCCH₂- radical.

n is 0 or 1,

R^B is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^A is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or Nmorpholinyl,

or R^A and R^B taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

19. (Withdrawn) The compound as claimed in claim 17 wherein n is 0, R^B is hydrogen and R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

Response to February 28, 2009 Office Action

20. (Withdrawn) The compound as claimed in claim 1 wherein R₃ is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. (Withdrawn) The compound as claimed in claim 1 wherein R_3 is a carboxamide group -CONR^B(Alk)_nR^A wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

- 22. (Withdrawn Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (IE) as defined in claim 1-, or a salt_-hydrate or solvate-thereof, effective to inhibit said HSP90 activity.
- 23. (Withdrawn Currently Amended) The method as claimed claim 22 for <u>treatment</u> of immunosuppression; or the treatment of cancer; viral disease, <u>diseases</u>; inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis. Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis; or angiogenesis-related <u>diseases</u> disease such as diabetic retinopathy, haemangiomas, and endometriosis; or <u>treatment</u> for protection of normal cells against chemotherapy-induced toxicity; or

Response to February 28, 2009 Office Action

<u>treatment of diseases</u> where failure to undergo apoptosis is an underlying factor; or <u>treatment for protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; <u>or treatment of scrapie/CJD</u>, Huntingdon's <u>disease or and-Alzheimer's disease</u>.</u>

24. (Cancelled)

25. (Currently Amended) A pharmaceutical or veterinary composition comprising a compound as defined in claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.